160 Health International (SEHK:2656) Loss Narrowing Challenges Bearish Narratives On Profit Path

160 Health International (SEHK:2656) has reported first half FY 2025 revenue of C¥290.7 million with a basic EPS loss of C¥0.07, against the backdrop of a 5% revenue increase over the last twelve months while the business remained unprofitable. Over recent periods, revenue has moved from C¥273.8 million in the first half of FY 2024 to C¥290.7 million in the first half of FY 2025, while trailing twelve month basic EPS has ranged between losses of roughly C¥0.15 and C¥0.39. This has kept margins in loss making territory even as the top line edged higher. With sales ticking up but earnings still in the red, the latest results put the focus squarely on whether the current cost base can support a path to healthier margins.

See our full analysis for 160 Health International.

With the headline numbers in place, the next step is to set these results against the most widely held stories about 160 Health International and see where the earnings data backs them up or calls them into question.

Curious how numbers become stories that shape markets? Explore Community Narratives

Loss narrows from C¥82.6m to C¥19.1m

• First half FY 2025 net loss came in at C¥19.1 million compared with C¥82.6 million in the first half of FY 2024, while basic EPS moved from a loss of C¥0.28 to a loss of C¥0.07 over the same periods.
• What jumps out for a more bullish read is that this smaller loss in the latest half sits within trailing twelve month net losses of C¥73.0 million on C¥651.9 million of revenue. This means:
  • Supporters of the more optimistic view can point to several periods where losses, such as C¥44.2 million in the prior twelve month snapshot, were lower than earlier twelve month losses above C¥100 million.
  • At the same time, bears can still highlight that every trailing twelve month period listed, from C¥110.7 million to C¥72.99 million of net losses, remains in negative territory, so the business has not yet turned that revenue base into positive earnings.

To see how other investors connect these earnings trends to a longer term story, check out how the community frames 160 Health International’s potential and risks in more depth Curious how numbers become stories that shape markets? Explore Community Narratives.

Unprofitable on C¥651.9m of trailing revenue

• Looking at the bigger picture, the trailing twelve month revenue reached C¥651.9 million while net income excluding extra items was a loss of C¥73.0 million, so the company is still loss making over the full year view.
• Bears often focus on the fact that repeated trailing twelve month losses, from C¥113.8 million down to C¥72.99 million alongside revenue that has generally sat between C¥525.6 million and C¥651.9 million, show a business that has not yet converted sales scale into profits:
  • Critics highlight that even when revenue moved above C¥600 million in multiple trailing periods, net losses stayed above C¥70 million, which keeps profitability risk front and center.
  • Supporters of a more positive stance may still point out that losses have been smaller in recent trailing periods than earlier ones, but the fact remains that every data point provided for net income is a loss.

P/S of 45.9x is far above peers

• The shares trade on a P/S of 45.9x, which is much higher than the 1x average for the Hong Kong healthcare industry and the 5.7x level for peers, even though the company was unprofitable over the trailing twelve months.
• For a more cautious investor, this high sales multiple together with recent share price volatility and ongoing losses creates a clear tension between price and fundamentals:
  • Skeptics point out that with a trailing twelve month loss of C¥73.0 million on C¥651.9 million of revenue, the current P/S of 45.9x leaves little room for comfort if revenue growth slows or costs stay elevated.
  • On the other hand, those willing to pay such a premium may be focusing on the 5% revenue growth over the past year, even though the available data does not yet show that this growth has translated into positive net income.

Next Steps

Don't just look at this quarter; the real story is in the long-term trend. We've done an in-depth analysis on 160 Health International's growth and its valuation to see if today's price is a bargain. Add the company to your watchlist or portfolio now so you don't miss the next big move.

Mixed signals on risk and opportunity so far? Take a closer look at the figures, act promptly, and form your own view by checking the 1 key reward and 1 important warning sign.

Explore Alternatives

160 Health International is still loss making on C¥651.9 million of trailing revenue, with a high 45.9x P/S multiple that many cautious investors may find hard to justify.

If that mix of ongoing losses and an expensive sales multiple feels uncomfortable, you can quickly compare it with companies screened for 278 resilient stocks with low risk scores to see options with potentially steadier profiles.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com